CytomX Therapeutics, Inc.

DB:6C1 Stock Report

Market Cap: €81.8m

CytomX Therapeutics Management

Management criteria checks 3/4

CytomX Therapeutics' CEO is Sean McCarthy, appointed in Aug 2011, has a tenure of 13.33 years. total yearly compensation is $2.61M, comprised of 25% salary and 75% bonuses, including company stock and options. directly owns 0.71% of the company’s shares, worth €578.23K. The average tenure of the management team and the board of directors is 3.7 years and 4.9 years respectively.

Key information

Sean McCarthy

Chief executive officer

US$2.6m

Total compensation

CEO salary percentage25.0%
CEO tenure13.3yrs
CEO ownership0.7%
Management average tenure3.7yrs
Board average tenure4.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Sean McCarthy's remuneration changed compared to CytomX Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

US$14m

Jun 30 2024n/an/a

US$11m

Mar 31 2024n/an/a

US$17m

Dec 31 2023US$3mUS$652k

-US$569k

Sep 30 2023n/an/a

-US$10m

Jun 30 2023n/an/a

-US$42m

Mar 31 2023n/an/a

-US$71m

Dec 31 2022US$3mUS$623k

-US$99m

Sep 30 2022n/an/a

-US$149m

Jun 30 2022n/an/a

-US$143m

Mar 31 2022n/an/a

-US$132m

Dec 31 2021US$4mUS$616k

-US$116m

Sep 30 2021n/an/a

-US$72m

Jun 30 2021n/an/a

-US$64m

Mar 31 2021n/an/a

-US$61m

Dec 31 2020US$3mUS$595k

-US$65m

Sep 30 2020n/an/a

-US$54m

Jun 30 2020n/an/a

-US$63m

Mar 31 2020n/an/a

-US$76m

Dec 31 2019US$4mUS$575k

-US$133m

Sep 30 2019n/an/a

-US$99m

Jun 30 2019n/an/a

-US$99m

Mar 31 2019n/an/a

-US$83m

Dec 31 2018US$5mUS$550k

-US$85m

Sep 30 2018n/an/a

-US$52m

Jun 30 2018n/an/a

-US$39m

Mar 31 2018n/an/a

-US$50m

Dec 31 2017US$3mUS$500k

-US$43m

Compensation vs Market: Sean's total compensation ($USD2.61M) is above average for companies of similar size in the German market ($USD469.36K).

Compensation vs Earnings: Sean's compensation has been consistent with company performance over the past year.

CEO

Sean McCarthy (57 yo)

13.3yrs

Tenure

US$2,611,138

Compensation

Dr. Sean A. McCarthy, D.Phil., serves as Independent Director at OncoResponse, Inc. since August 2021. He has been the Chief Executive Officer of CytomX Therapeutics, Inc. since August 2011 and has been it...

Leadership Team

NamePositionTenureCompensationOwnership
Sean McCarthy
Chairman & CEO13.3yrsUS$2.61m0.71%
€ 578.2k
Marcia Belvin
Senior VP & Chief Scientific Officer1.9yrsUS$1.21m0.085%
€ 69.4k
Jeffrey Landau
Senior VP3.7yrsUS$1.05m0.079%
€ 64.7k
Christopher Ogden
Chief Financial Officer2.3yrsno data0.039%
€ 31.6k
Lloyd Rowland
Senior VP6.6yrsUS$1.21m0.10%
€ 81.4k
Danielle Olander-Moghadassian
Senior VP & Chief Human Resources Officerno datano datano data
Leslie Robbins
Senior Vice President of Intellectual Property5.8yrsno datano data
Yu-Waye Chu
Chief Medical Officer1.4yrsno datano data
Dawn Benson
Senior Vice President of Quality & Product Manufacturing1.9yrsno datano data
Hoyoung Huh
Special Advisor to Chief Executive Officerno dataUS$273.54kno data

3.7yrs

Average Tenure

55.5yo

Average Age

Experienced Management: 6C1's management team is considered experienced (3.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Sean McCarthy
Chairman & CEO13.3yrsUS$2.61m0.71%
€ 578.2k
Elaine Jones
Independent Director5.6yrsUS$75.12k0.0066%
€ 5.4k
John Lambert
Member of Scientific Advisory Board4.9yrsno datano data
Louis Weiner
Member of Scientific Advisory Boardno datano datano data
Mani Mohindru
Independent Director4yrsUS$78.62k0%
€ 0
James Meyers
Independent Director6yrsUS$77.12k0%
€ 0
Matthew Young
Lead Independent Director9.3yrsUS$105.12k0%
€ 0
Halley Gilbert
Independent Director4.7yrsUS$80.62k0%
€ 0
W. Kavanaugh
Member of Scientific Advisory Board4yrsUS$8.03mno data
Alan Ashworth
Independent Director3.3yrsUS$69.12k0%
€ 0
Charles Sentman
Member of Scientific Advisory Board4.9yrsno datano data
Lisa Coussens
Member of Scientific Advisory Board1.9yrsno datano data

4.9yrs

Average Tenure

61yo

Average Age

Experienced Board: 6C1's board of directors are considered experienced (4.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 08:36
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CytomX Therapeutics, Inc. is covered by 17 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Etzer DaroutBMO Capital Markets Equity Research
Ying HuangBofA Global Research